TradeOrgs
  • 🇮🇳 India
  • 🇺🇸 US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← US stocks

🇺🇸ACRS

Aclaris Therapeutics, Inc. - Common Stock

NASDAQ
$3.44
▼ $0.33 (-8.8%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 20 Nov 2026
H $6.60L $3.18-29.2%
$6.6$5.92$5.23$4.55$3.87$3.18$3.45
RSI (14)
Intraday · 15-minStrong sell-45RSI 43DowntrendMACD Bearishfor day-trading context — not advice

Technical signal

Sell-30
RSI (14)38
oversold 30overbought 70
Trend
Downtrend
MACD
Bullish
Bollinger
Within bands
vs 20-day
below
vs 50-day
below
vs 200-day
below
Support
$3.28
Resistance
$4.40
  • Price is below its 50-day average (medium-term weakness).

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

Signal backtest · 2026-02-13 → 2026-11-17

Strategy return
-3.0%
Buy & hold
+8.3%
Trades
6
Win rate
33%

$100,000.00 invested would be worth $96,958.14 (-3.0%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Aclaris Therapeutics, Inc.· Biotechnology

source: yahoo

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Sector
Healthcare
Industry
Biotechnology
Employees
69
Headquarters
Wayne, United States
www.aclaristx.com ↗

Fundamentals

No fundamental data is currently available for this listing from our data providers.

Recent news

News sentiment:▼ Negative0↑ · 2↓ · 6–
  • Wedbush Downgrades Aclaris Therapeutics to Neutral From Outperform, Cuts Price Target to $3 From $8— Neutral
    MT Newswires · 17 Nov 2026
  • Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection— Neutral
    CNW Group · 16 Nov 2026
  • Aclaris stock falls after atopic dermatitis trial fails▼ Negative
    Investing.com · 16 Nov 2026
  • Aclaris Therapeutics’ mAb fails in Phase II eczema trial
— Neutral
Clinical Trials Arena · 16 Nov 2026
  • Why is Aclaris Therapeutics Stock Trading Lower on Monday?— Neutral
    Benzinga · 16 Nov 2026
  • Aclaris Therapeutics Begins Phase 2b Trial of Lichen Planus Treatment— Neutral
    MT Newswires · 16 Nov 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.